Remove Litigation Remove Patent Remove Settlement
article thumbnail

Competition Bureau closes two investigations into pharmaceutical patent litigation settlements

JD Supra Law

On May 20, 2022, the Competition Bureau announced that it closed two investigations into pharmaceutical patent litigation settlement agreements as evidence gathered during the two investigations suggested the agreements did not contravene the Competition Act. The parties and drugs involved were not identified.

article thumbnail

A Decade of FTC v. Actavis: The Reverse Payment Framework is Older, but Are Courts Wiser in Applying It

JD Supra Law

In 2013, the United States Supreme Court significantly changed the landscape of patent settlements in the pharmaceutical industry with its FTC v. Actavis, Inc.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ANDA Litigation Settlements - Summer 2021

JD Supra Law

This chart summarizes the case name, drug, patents-in-suit, and publicly available terms for reported settlements in federal district court cases that are filed pursuant to the Hatch-Waxman Act. By: Robins Kaplan LLP

article thumbnail

Longford Argues Patent Settlement Row Must Be Arbitrated

IP Law 360

Litigation funder Longford Capital has asked a Delaware federal court to send its dispute over a settlement with Arigna Technology Ltd. to arbitration, saying the arbitration agreement between the two parties is valid despite the Irish patent holding company's claims otherwise.

article thumbnail

Litigation as a Source of Profit? Non-Practicing Entities and Patent Litigation

IPilogue

Litigation is almost always recommended to be avoided , whether because of the sheer amount of time needed to get a court date, the expensive costs for the client and law firm, or the risks associated with receiving an unfavorable judgement. They do not practice, develop, manufacture, or otherwise commercialize the patent.

article thumbnail

Genentech and Tanvex Reach Settlement in Principle in Trastuzumab BPCIA Litigation

JD Supra Law

On January 6, 2023, Genentech and Tanvex reached a settlement in principle to resolve all claims with respect to Genentech’s BCPIA complaint.

article thumbnail

ANDA Litigation Settlements - Reported Settlements in Federal District Court Cases

JD Supra Law

This chart summarizes the case name, drug, patents-in-suit, and publicly available terms for reported settlements in federal district court cases that are filed pursuant to the Hatch-Waxman Act. By: Robins Kaplan LLP